{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:01:43Z","timestamp":1790193703621,"version":"4.1.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100013057","name":"Heffter Research Institute","doi-asserted-by":"publisher","award":["140289"],"award-info":[{"award-number":["140289"]}],"id":[{"id":"10.13039\/100013057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acad Psychiatry"],"DOI":"10.1007\/s40596-026-02444-3","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:15:26Z","timestamp":1790190926000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Multi-Site Evaluation of a Psychedelic Medicine Curriculum for Psychiatry Trainees"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4981-8335","authenticated-orcid":false,"given":"Mary E.","family":"Yaden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelley C.","family":"O\u2019Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noam","family":"Goldway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praachi","family":"Tiwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terence H. W.","family":"Ching","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamila","family":"Hokanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Gukasyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan","family":"Appold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Glick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Kelmendi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Pittenger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"issue":"4","key":"2444_CR1","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1089\/psymed.2023.0011","volume":"1","author":"KC O'Donnell","year":"2023","unstructured":"O\u2019Donnell KC, Roberts DE, Ching THW, Glick G, Goldway N, Gukasyan N, Hokansen J, Kelmendi B, Ross S, Yaden ME, Pittenger C. What is in a name? The many meanings of \u201cpsychedelic.\u201d Psychedelic Med. 2023;1(4):187\u20139. https:\/\/doi.org\/10.1089\/psymed.2023.0011.","journal-title":"Psychedelic Med"},{"key":"2444_CR2","unstructured":"Chen E (2025) Compass Pathways expects earlier FDA approval decision on its psilocybin drug. STAT News. https:\/\/www.statnews.com\/2025\/11\/04\/compass-pathways-depression\/. Accessed 15 March 2026"},{"issue":"2","key":"2444_CR3","doi-asserted-by":"publisher","first-page":"42","DOI":"10.18192\/uojm.v15i2.7456","volume":"15","author":"S Sampy","year":"2025","unstructured":"Sampy S, Sampy R. The psychedelic frontier: a cross-specialty review of healthcare providers\u2019 attitudes on psychedelic-assisted therapy in the US. Univ Ottawa J Med. 2025;15(2):42\u201353. https:\/\/doi.org\/10.18192\/uojm.v15i2.7456.","journal-title":"Univ Ottawa J Med"},{"issue":"3","key":"2444_CR4","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1080\/02791072.2021.1957183","volume":"54","author":"BS Barnett","year":"2022","unstructured":"Barnett BS, Beaussant Y, King IVF, Doblin R. Psychedelic knowledge and opinions in psychiatrists at two professional conferences: an exploratory survey. J Psychoactive Drugs. 2022;54(3):269\u201377. https:\/\/doi.org\/10.1080\/02791072.2021.1957183.","journal-title":"J Psychoactive Drugs"},{"key":"2444_CR5","doi-asserted-by":"publisher","unstructured":"Barnett BS, Arakelian M, Weleff J, Squier-Roper T, King F 4th, Cumming D, Falcone T. Psychiatric residents\u2019 perspectives on psychedelics and psychedelic assisted therapy. J Psychoactive Drugs. 2025. https:\/\/doi.org\/10.1080\/02791072.2025.2527296.","DOI":"10.1080\/02791072.2025.2527296"},{"issue":"8","key":"2444_CR6","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1080\/09540261.2024.2397039","volume":"36","author":"ME Yaden","year":"2024","unstructured":"Yaden ME, Ching THW, Goldway N, Roberts DE, Hokanson J, Gukasyan N, Pittenger C, Kelmendi B, Ross S, Glick G, O\u2019Donnell KC. Psychedelic medicine in psychiatry residency training: a survey of psychiatric residency program directors. Int Rev Psychiatry. 2024;36(8):902\u20137. https:\/\/doi.org\/10.1080\/09540261.2024.2397039.","journal-title":"Int Rev Psychiatry"},{"issue":"1","key":"2444_CR7","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s40596-022-01662-9","volume":"47","author":"WL Prueitt","year":"2023","unstructured":"Prueitt WL, Sloshower J. Psychedelic medicine: creating an introductory course for mental health professionals and trainees. Acad Psychiatry. 2023;47(1):74\u20137. https:\/\/doi.org\/10.1007\/s40596-022-01662-9.","journal-title":"Acad Psychiatry"},{"issue":"1","key":"2444_CR8","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1080\/19585969.2024.2398456","volume":"26","author":"S Chaudhry","year":"2024","unstructured":"Chaudhry S, Weisman AE, Hagen M, Pauli KLS, Tabaac BJ. Examining the influence of team-based learning on medical students\u2019 comprehension and attitudes regarding psychedelic therapies. Dialogues Clin Neurosci. 2024;26(1):56\u201363. https:\/\/doi.org\/10.1080\/19585969.2024.2398456.","journal-title":"Dialogues Clin Neurosci"},{"key":"2444_CR9","volume-title":"Curriculum development for medical education: a six-step approach","author":"PA Thomas","year":"2009","unstructured":"Thomas PA, Kern DE, Hughes MT. Curriculum development for medical education: a six-step approach. 2nd ed. Johns Hopkins University Press; 2009.","edition":"2nd ed"},{"issue":"3","key":"2444_CR10","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1080\/02791072.2024.2341795","volume":"57","author":"J Geller","year":"2025","unstructured":"Geller J, Glynos N, Lemmen A, Pacilio R, Kruger DJ, Hosanagar A. Trainees unprepared for advances in psychedelic medicine: a survey study. J Psychoactive Drugs. 2025;57(3):235\u201342. https:\/\/doi.org\/10.1080\/02791072.2024.2341795.","journal-title":"J Psychoactive Drugs"},{"key":"2444_CR11","unstructured":"Psychedelic Education Partnership. Psychedelic education partnership launches to advance evidence-based education for the health care workforce. Newswise. Published March 17, 2026. Accessed July 2, 2026. https:\/\/www.newswise.com\/articles\/psychedelic-education-partnership-launches-to-advance-evidence-based-education-for-the-health-care-workforce"}],"container-title":["Academic Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40596-026-02444-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40596-026-02444-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40596-026-02444-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:15:28Z","timestamp":1790190928000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40596-026-02444-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":11,"alternative-id":["2444"],"URL":"https:\/\/doi.org\/10.1007\/s40596-026-02444-3","relation":{},"ISSN":["1042-9670","1545-7230"],"issn-type":[{"value":"1042-9670","type":"print"},{"value":"1545-7230","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]},"assertion":[{"value":"15 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The survey reported in this study was granted exemption from full-board review by the Institutional Review Board of the Johns Hopkins School of Medicine (IRB00340606). This research was conducted in accordance with the ethical principles set out in the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MY received support from the Heffter Research Institute, Steven and Alexandra Cohen Foundation, Valor Philanthropic, Psychedelic Educators Network, and the Department of Defense. KCO and THWC have received compensation for their roles as faculty in the Psychedelic-Assisted Therapy Training Program offered by Integrative Psychiatry Institute (IPI). KCO receives salary and travel support from philanthropic contributions from the Heffter Research Institute. She has also received compensation from MAPS-PBC and the Polaris Insight Center Psychedelic Therapist Training Program for her teaching roles in the MDMA Therapist Training Program and for an educational presentation, respectively, honorarium from Psych Congress for an educational lecture, and consulting fees from Mosaic. THWC has also received consulting fees for Transcend Therapeutics. DER reports receiving consulting fees from Fluence International, Inc., Guidepoint Global, LLC, and AlphaSights Ltd., travel and lodging support from Reunion Neuroscience, and honoraria from various organizations for speaking engagements and scientific review activities. JH has received honorarium for speaking engagements at Brown University and University of California Berkeley. NG reports serving as a site principal investigator on clinical trials sponsored by Helus Pharma and Reunion Neuroscience, and receiving consulting fees from MMS Holdings. She also received grant support from the Steven and Alexandra Cohen Foundation, a speaking fee from the MIND foundation for a continuing education course, and travel\/conference fees from MAPS. BK is a principal investigator and THWC and JH are co-investigators on clinical trials funded by Heffter Research Institute, the Steven and Alexandra Cohen Foundation, Usona Institute, and Helus Pharma. He reports additional grants or contracts from the National Institute on Mental Health (NIMH) and the State of Connecticut (paid to his institution). He receives personal royalties from data on psilocybin for OCD; he was personally paid consulting fees from and owns equity in Transcend Therapeutics. SR has received grant support for clinical research, over the last 36\u00a0months, from the National Institute on Drug Abuse, National Cancer Institute, National Institute on Aging, Usona Institute, Mind Medicine, Reset Pharmaceuticals, and Reunion Neuroscience. SR is listed as a co-inventor in two provisional patent applications (N420838US and N419987US) related to the use of psilocybin to treat psychiatric and existential distress in cancer, filed by New York University Grossman School of Medicine and licensed by Reset Pharmaceuticals. SR has waived all rights and has no prospect of financial gain in relation to these patent applications. CP has consulted in the past 3\u00a0years for Freedom Biotechnology, Mind Therapeutics, and Biohaven Pharmaceuticals, and receives research funding from the Heffter Foundation, the Steven and Alexandra Cohen Foundation, the Taylor Family Foundation, Transcend Pharmaceuticals, Ceruvia Life Sciences, Freedom Biotechnology, Biohaven Pharmaceuticals, the National Institutes of Health, the Brain and Behavior Research Foundation, the Colton Center for Autoimmunity at Yale, and the Department of Defense\/Congressionally Mandated Research Programs. He is an inventor on patents related to novel psychedelic drug combinations, autoantibodies implicated in neuroimmune pathogenesis, and novel pharmacotherapies for OCD, Tourette syndrome, and related conditions. He receives\/has received royalties from Oxford University Press, UpToDate, Biohaven Pharmaceuticals, and Ceruvia Lifesciences. He has equity in Mind Therapeutics, Alco Therapeutics, Loop Bio (pending), and Lucid\/care (pending). The authors declare that the content of this manuscript reflects their independent scholarly work and that no funder had any role in the design, conduct, or reporting of this educational project.","order":2,"name":"Ethics","label":"Disclosures","group":{"name":"EthicsHeading","label":"Declarations"}}]}}